Posted by Michael Wonder on 16 Dec 2023
Has the Centers for Medicare Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations?
15 December 2023 - The US Inflation Reduction Act of 2022 created several major policy changes to the pricing of prescription drugs under Medicare.
Arguably, the most significant reform requires the CMS to directly negotiate prescription drug prices with the pharmaceutical industry for top spending Medicare Part B and D drugs.
In this commentary, we show the first 10 drugs selected by CMS. We then describe the process and evidence considered in establishing the initial price offer and discuss what we believe to be the inherent value framework underlying the initial price offer and its implications for evidence generation.
